Moderna is testing a new vaccine for the South African Corona strain

The American company, Moderna, for the pharmaceutical industry revealed, yesterday, Wednesday, that doses of its new vaccine that targets the South African strain of the emerging corona virus have been sent to the US National Institutes of Health for testing.

"We are looking forward to starting clinical trials of the variable anti-virus booster vaccine, and we are grateful for the continued cooperation with the National Institutes of Health to confront this epidemic," said the company's president, Stephan Bancel.

The South African strain is among the most dangerous current virus mutations, as it is able to avoid antibodies that target older strains of the Corona virus.

This means that people who have contracted the classic strain are more likely to be infected again, and research has shown that the South African strain has partially reduced the protection of some current generations from vaccines.

While initial experiments showed that the original Moderna vaccine called "MRNA-1273" remains effective against the new strains, the company said it is seeking to develop a vaccine for these strains as part of several strategies being studied.

Either a special candidate vaccine against the South African strain named "MRNA-1273.351" is used as a protection booster, or the company may use a booster vaccine that combines the classic vaccine with that of the new strain to create a product from the new mixture.

Another idea being considered is for people to receive a third dose of the classic vaccine to boost their immunity.

And the US Food and Drug Administration (FDA) announced, on Monday, that pharmaceutical companies that develop vaccines for new strains do not need to go through the same long and complicated process in order to obtain licenses for basic vaccines.

Follow our latest local and sports news, and the latest political and economic developments via Google news